Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …

Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …

Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …

Precision medicine is an approach that takes into account the influence of individuals'
genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the …

Background Inherited mutations in DNA-repair genes such as BRCA2 are associated with
increased risks of lethal prostate cancer. Although the prevalence of germline mutations in …

High-throughput genomic analyses may improve outcomes in patients with advanced
cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this …

An increasingly recognized resistance mechanism to androgen receptor (AR)-directed
therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low …

Importance Use of next-generation sequencing (NGS) to identify clinically actionable
genomic targets has been incorporated into routine clinical practice in the management of …

Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …